Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
45
datasets available to search
ShareScore release 0.9.0
Dataset results
45 results for “H7N9”
2013/2017 H7N9 Prime-Boost Interval
ClinicalTrials.gov study NCT03589807. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
ClinicalTrials.gov study NCT03312231. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Dissemination, divergence and establishment of H7N9 influenza viruses in China
Since 2013 the occurrence of human infections by a novel avian H7N9 influenza virus in China has demonstrated the continuing threat posed by zoonotic pathogens. Although the first outbreak wave that was centred on eastern China was seemingly averted, human infections recurred in October 2013. It is unclear how the H7N9 virus re-emerged and how it will develop further; potentially it may become a long-term threat to public health. Here we show that H7N9 viruses have spread from eastern to southern China and become persistent in chickens, which has led to the establishment of multiple regionally distinct lineages with different reassortant genotypes. Repeated introductions of viruses from Zhejiang to other provinces and the presence of H7N9 viruses at live poultry markets have fuelled the recurrence of human infections. This rapid expansion of the geographical distribution and genetic diversity of the H7N9 viruses poses a direct challenge to current disease control systems. Our results also suggest that H7N9 viruses have become enzootic in China and may spread beyond the region, following the pattern previously observed with H5N1 and H9N2 influenza viruses.
Data from: Association between the severity of influenza A(H7N9) virus infections and length of the incubation period
Background: In early 2013, a novel avian-origin influenza A(H7N9) virus emerged in China, and has caused sporadic human infections. The incubation period is the delay from infection until onset of symptoms, and varies from person to person. Few previous studies have examined whether the duration of the incubation period correlates with subsequent disease severity. Methods and Findings: We analyzed data of period of exposure on 395 human cases of laboratory-confirmed influenza A(H7N9) virus infection in China in a Bayesian framework using a Weibull distribution. We found a longer incubation period for the 173 fatal cases with a mean of 3.7 days (95% credibility interval, CrI: 3.4–4.1), compared to a mean of 3.3 days (95% CrI: 2.9–3.6) for the 222 non-fatal cases, and the difference in means was marginally significant at 0.47 days (95% CrI: -0.04, 0.99). There was a statistically significant correlation between a longer incubation period and an increased risk of death after adjustment for age, sex, geographical location and underlying medical conditions (adjusted odds ratio 1.70 per day increase in incubation period; 95% credibility interval 1.47–1.97). Conclusions: We found a significant association between a longer incubation period and a greater risk of death among human H7N9 cases. The underlying biological mechanisms leading to this association deserve further exploration.
Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old
ClinicalTrials.gov study NCT02274545. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil
ClinicalTrials.gov study NCT03330899. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
ClinicalTrials.gov study NCT01995695. IPD Sharing: Not stated. Countries: 1. Publications: 1.
H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime
ClinicalTrials.gov study NCT02206464. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1
ClinicalTrials.gov study NCT01897701. IPD Sharing: Not stated. Countries: 1. Publications: 1.
H7N9 Mix and Match With MF59 in Healthy Adults
ClinicalTrials.gov study NCT01938742. IPD Sharing: Not stated. Countries: 1. Publications: 2.
H7N9 Boost in Healthy Adults
ClinicalTrials.gov study NCT02586792. IPD Sharing: Not stated. Countries: 1. Publications: 1.
H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
ClinicalTrials.gov study NCT01942265. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects
ClinicalTrials.gov study NCT02436928. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Dissemination, divergence and establishment of H7N9 influenza viruses in China
Open the record for dataset details and reuse information.
Data from: Association between the severity of influenza A(H7N9) virus infections and length of the incubation period
Open the record for dataset details and reuse information.
Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine
ClinicalTrials.gov study NCT02480101. IPD Sharing: Not stated. Countries: 0. Publications: 1.
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
ClinicalTrials.gov study NCT02921997. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine
ClinicalTrials.gov study NCT03739229. IPD Sharing: NO. Countries: 0. Publications: 1.
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
ClinicalTrials.gov study NCT01928472. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Human Calu-3 cell micro RNA transcriptome response to a wild type infectious clone of H7N9 Influenza virus and mutant H7N9 viruses
GEO Series GSE69027. Homo sapiens. 24 samples. Type: Non-coding RNA profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.